share_log

四川百利天恒药业股份有限公司自愿披露关于BL-B01D1(EGFR×HER3-ADC)用于局部晚期或转移性EGFR野生型非小细胞肺癌III期临床试验完成首例受试者入组的公告

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that BL-B01D1 (EGFR×HER3-ADC) for locally advanced or metastatic EGFR wild-type non-small cell lung cancer phase III clinical trial completed

Sensex a share ·  Jun 2
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more